Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tocilizumab in COVID-19: The Cerrahpaşa-PREDICT score.
Eşkazan AE, Balkan İİ, Demirbaş KC, Ar MC, Karaali R, Sekibağ Y, Mulamahmutoğlu S, Yartaş Dumanlı G, Çakmak F, Özgür Yurttaş N, Kurt F, Aladağ Kurt S, Kuşkucu M, Ürkmez S, Börekçi Ş, Saribal D, Mete B, Bavunoğlu I, Dikmen Y, Aygün G, Midilli K, Tabak F. Eşkazan AE, et al. J Infect Chemother. 2021 Sep;27(9):1329-1335. doi: 10.1016/j.jiac.2021.05.007. Epub 2021 May 12. J Infect Chemother. 2021. PMID: 34120824 Free PMC article.
Intracranial mass in a patient with thalassaemia major.
Eskazan AE, Ar MC, Baslar Z. Eskazan AE, et al. Br J Haematol. 2011 Jan;152(2):126. doi: 10.1111/j.1365-2141.2010.08493.x. Epub 2010 Nov 23. Br J Haematol. 2011. PMID: 21175566 Free article. No abstract available.
First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.
Eskazan AE, Ayer M, Kantarcioglu B, Arica D, Demirel N, Aydin D, Yalniz FF, Elverdi T, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Eskazan AE, et al. Br J Haematol. 2014 Oct;167(1):139-41. doi: 10.1111/bjh.12937. Epub 2014 May 10. Br J Haematol. 2014. PMID: 24815307 Free article. No abstract available.
Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.
Eskazan AE, Eyice D, Kurt EA, Elverdi T, Yalniz FF, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z, Ferhanoglu B, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Eskazan AE, et al. Leuk Res. 2014 Jul;38(7):781-7. doi: 10.1016/j.leukres.2014.04.004. Epub 2014 Apr 18. Leuk Res. 2014. PMID: 24832371
168 results